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ABSTRACT 
Background 
Immune thrombocytopenia (ITP) is an acquired, autoimmune disorder where 
antiplatelet antibodies are directed to both platelets and megakaryocytes resulting in 
increased platelets destruction and inadequate platelet production. T-cells also play 
a role in autoantibody production as well as in direct lysis of platelets (cytotoxic T-
cells). 
 
The presentation of adult ITP may be acute or insidious in onset. Most cases go on 
to develop chronic ITP. Primary ITP accounts for approximately 80% of the patients 
and secondary ITP for 20%. However, in South Africa, there is a paradigm shift with 
an increasing number of patients with secondary ITP, contributed to mainly by 
human immunodeficiency virus (HIV) infection. 
 
Splenectomy is the most definitive therapy for ITP. It has the highest likelihood of all 
the current treatment options of producing a cure. The overall response rate is 70-
90% (CR 50-60%, PR 20-30%, relapse rate 15%). It is effective for persistent and 
chronic ITP after failure of corticosteroid therapy. It is recommended that 
splenectomy be delayed for at least six months (and preferably 12 months) from 
diagnosis due to the chance of a spontaneous remission (5-11%). Although open 
splenectomy and laparoscopic splenectomy have similar efficacy, laparoscopic 
splenectomy has fewer surgical complications, including less postoperative pain, 
earlier general diet tolerance and shorter hospital stay. 
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There is a paucity of data with regard to ITP, and more specifically, looking at the 
efficacy and safety of splenectomy in the South African context. Furthermore, in view 
of the increased prevalence of HIV as the most common cause of secondary ITP, it 
is important to ascertain the feasibility, safety and efficacy of splenectomy in 
secondary ITP. 
 
Therefore, the current study aimed at exploring the impact of splenectomy as a 
therapeutic option in ITP, in adults at CHBAH over a period of 29 years (01/01/1986- 
31/12/2014). 
 
Patients and Methods 
This is a retrospective review of the records of ITP patients who had a splenectomy, 
during the aforementioned study period at the Clinical Haematology unit, Chris Hani 
Baragwanath Academic Hospital. 
 
The aim of the study was to study the impact of splenectomy as a therapeutic 
modality in patients with ITP, specifically looking at the indication, timing, outcome, 
response, duration of response and complications of splenectomy in ITP. The 
efficacy and safety of laparoscopic versus open splenectomy in ITP was assessed 
as well as a comparison of the efficacy, safety and outcome of splenectomy in 
primary and secondary ITP.  
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Results and Discussion 
A total of 56 splenectomised ITP patients’ records were reviewed. Of these, 43 were 
female (77%) while 13 were male (23%). The median age of the patients was 29 
years, with a range of 18- 53 years. 
 
Majority of the patients had primary ITP (n=42, 75%), and the remaining (n=14, 25%) 
had secondary ITP. Of the fourteen patients with secondary ITP who had a 
splenectomy, 11 had an underlying autoimmune aetiology. Nine patients (82%) were 
diagnosed with SLE while concomitant auto-immune haemolytic anaemia (Evan’s 
syndrome) and mixed connective tissue disease accounted for 1 each (18%), of the 
remaining patients, respectively.  
 
In this study, there were three HIV positive patients who had a splenectomy 
accounting for 5.4% of all splenectomised patients with ITP. 
 
The surgery of choice in this study was open splenectomy (n=51, 91%). Only five 
patients underwent laparoscopic splenectomy of which two were later converted to 
open splenectomy because of complications. 
 
Failed corticosteroid (CS) therapy (98.2%) was the commonest indication for 
splenectomy in this study. These patients were either steroid dependent or showed 
only a partial response. Similarly, they also experienced disabling side effects from 
high doses and/or prolonged use of CS therapy. One patient had splenectomy as a 
result of poor compliance (1.8%). 
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In the splenectomised patients, platelet counts one year post splenectomy (mean = 
231.19 x 109/l ± 162.643) were significantly higher than the platelet counts prior to 
splenectomy (mean = 26.22 x 109/l ± 31.552 and p-value= 0.00). 
 
Three patients (5.4%) experienced infections requiring hospitalization. Two patients 
had thrombotic complications, while five patients had bleeding manifestations up to 
the time of the last visit. 
 
Overall, 37 patients (66%) had a complete remission, while seven patients (12.5%) 
had a partial remission. Six patients (10.8%) showed no response to splenectomy. In 
four patients (7%), the outcome was unknown. Two patients (3.6%) died, one patient 
from a complication of surgery and the other patient from sepsis four years post 
splenectomy. 
 
Conclusion 
The role of splenectomy in ITP continues to be reassuring, particularly in our setting 
where the ‘newer’ agents, such as rituximab (used as an off-label indication in ITP), 
and thrombomimetics, which are not yet accessible due to high cost, are challenging 
the role of splenectomy. Splenectomy is the preferred second line therapy after the 
patient has failed CS therapy.  Although the minority of the patients had a 
laparoscopic splenectomy, with time and experience, laparoscopic splenectomy 
should become the procedure of choice, especially in conditions such as ITP, where 
the spleen is not enlarged, and the procedure is highly technically feasible. 
Furthermore, the outcome for primary versus secondary ITP was equally favourable. 
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However, there were significantly less number of secondary ITP patients in this 
study. 
 
The findings in this study are limited by its retrospective nature. For some patients 
data was missing and the files could not be reviewed. Ideally, a larger sample size 
would have added to the strength of this study. Nevertheless, we believe that the 
findings are a fair representation of the role of splenectomy in ITP, in the public 
sector South African context, based on this retrospective review from a large single 
centre, over a period of 29 years. Therefore, splenectomy remains a therapeutic 
modality of choice in this setting, particularly in patients with persistent and chronic 
ITP, who have failed prior CS therapy.   
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 Introduction 
Immune Thrombocytopenia (ITP) is an acquired, autoimmune disorder where 
antiplatelet antibodies are directed to both platelets and megakaryocytes resulting in 
increased platelets destruction and inadequate platelet production. T-cells also play 
a role in autoantibody production as well as in direct lysis of platelets (cytotoxic T-
cells).1,2,3 
 
1.2 Historical Background 
The classical clinical description of ITP was first reported in 1735 by a German 
physician, Paul Gottlieb Werlhof, in a young girl who presented with epistaxis, 
hematemesis and purpura.4 This was long before platelets were described by Max 
Schultze in 1865 and later by William Osler in 1874, as a distinct cellular constituent 
of blood.5,6 It was only in 1883 that the link between thrombocytopenia and purpura 
was established by Brohm.7 This observation was supported by Denys in 1887, when 
he noted that platelets were reduced during the active phase of purpura and 
increased when bleeding stopped.8,9 The following century witnessed the search for 
the pathogenic mechanisms of ITP. While there was an ongoing debate among the 
earlier researchers on the pathogenesis of ITP, a breakthrough came in the 
management of the disease in 1916 when Paul Kaznelson, a Polish medical student 
reported the benefit of splenectomy in this disorder. He noted that platelet counts 
increased significantly in a young woman with ITP, post splenectomy.9,10 
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1.3 Epidemiology 
 
The incidence of newly diagnosed primary ITP is approximately 3 - 4.5 /100 000 
/year. There is a higher prevalence of chronic ITP which is 10 - 25/100 
000/year.11,12,13,14 The true incidence of newly diagnosed ITP in South Africa is 
unknown, but it is estimated to be approximately 1 - 2 / 100 000 /year.15,16 ITP 
(primary) is a disease predominantly affecting young females. This is based on two 
local South African studies where the median ages were 31 years (with a female to 
male ratio of 4.1:1), and a mean age of 34 years (with a female to male ratio of 
5.2:1).15,16 However, in a population based European study, the median age is 
approximately two decades later (approximately 57 years), with an increasing 
incidence with advancing age (>60 years). The gender difference of a female 
predominance in young and middle aged individuals is also less marked in patients 
above the age of 60 years.11,13,14 
 
Primary ITP accounts for approximately 80% of the patients and secondary ITP for 
20%. However, in South Africa, based on a recent review, there is a paradigm shift 
with an increasing number of patients with secondary ITP, contributed to mainly by 
human immunodeficiency virus (HIV) infection.16In this review secondary ITP 
accounted for 50% of cases of which 40% of this were attributed to HIV infection. 
 
1.4 Definitions and Terminology 
The normal platelet count ranges between 150 - 400 x 109/l. Local South African 
studies have shown some variability in the level of the platelet counts, including 
studies performed by Tikly et al, 1987 and Lawrie et al, 2009, who found the 
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following normal ranges (M: 164 – 396 x 109/l; F: 191 – 442 x 109/l) and (M: 171 - 
388 x 109/l; F: 186 - 454 x 109/l), respectively.17,18  Despite the lower limit of normal 
being well above 100 x 109/l, platelet counts below the lower limit of normal and 
above 100 x 109/l are generally not associated with any clinical manifestations. 
Therefore, the threshold for ITP and indeed for clinical thrombocytopenia is defined 
as a platelet count of < 100 x 109/l.19 
 
Due to the difficulty posed by lack of standardization of clinical criteria for the 
diagnosis and management of ITP in clinical practice and in research, the 
International Working Group (IWG) on ITP in 2007, came up with a document or 
proposal to address this problem. Their recommendations have been widely adopted 
by many clinical guidelines. ITP now refers to Immune Thrombocytopenia (ITP) and 
no longer to terminologies such as immune or idiopathic thrombocytopenic 
purpura.19 
 
Primary immune thrombocytopenia is a diagnosis of exclusion once all other causes 
are excluded. This requires detailed history – including family history, prior history of 
bleeding and bleeding after haemostatic challenges, drug history and complete 
physical examination). Thereafter, other known causes of immune mediated 
thrombocytopenia referred to as secondary ITP should be excluded. This includes 
drugs such as rifampicin, quinine and heparin, infections such as HIV, autoimmune 
disease including systemic lupus erythematosus (SLE) and lymphoproliferative 
disorders (LPD) such as chronic lymphocytic leukaemia (CLL) and lymphoma. 
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Table 1.1 Causes of secondary ITP 
1. Infections HIV, hepatitis C, EBV, Malaria, VZV, H. Pylori  
2. Drugs Heparin, rifampicin, quinine, quinidine, penicillin, 
ATG, captopril etc. 
3. Lymphoproliferative  CLL, Lymphoma 
4. Auto-immune SLE, APLS, auto-immune hepatitis, auto- immune 
thyroiditis 
5. Other Evans syndrome, Auto-immune lymphoproliferative 
syndrome, CVID 
 
EBV- Epstein Barr Virus; VZV- Varicella Zoster Virus; H. Pylori- Helicobacter Pylori; ATG- Anti-thymocyte globulin; HIV- Human 
Immunodeficiency Virus. CLL- Chronic lymphocytic leukaemia; APLS- Auto-immune lymphoproliferative syndrome; CVID- Common variable 
immunodeficiency 
 
There are no specific clinical or laboratory parameters to establish the diagnosis, and 
the diagnosis remains one of exclusion. Abnormal clinical features such as 
lymphadenopathy or hepatosplenomegaly (in the absence of bleeding) should 
suggest another cause of thrombocytopenia or a secondary cause of ITP.  
 
Furthermore, three distinct phases of the disease are recognized in primary ITP: 
I. Newly diagnosed (from diagnosis to 3 months) 
II. Persistent (from 3 to12 months) 
III. Chronic (>12 months)19 
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The International Working Group (IWG) also recognizes the platelet count as a 
surrogate measure of important clinical end points such as bleeding and quality of 
life, with regard to determining response to therapy.  
Different categories of response are defined: 
i. Complete response (CR) is defined as a platelet count equal to or more than 
100 x 109/l,  
ii. Response (R) is defined as any platelet count between 30 and 100 x 109/l and 
at least doubling of the baseline count, and 
iii. No Response (NR) is defined as any platelet less than 30 x 109/l or less than 
doubling of the baseline count. 
 
1.5 Aetiopathogenesis 
Since 1951, when Harrington et al, demonstrated that ITP is characterized by 
reduced platelet survival due to a humoral factor, much has been gained in our 
understanding of the pathogenic mechanisms of ITP.20 
 
Immune Thrombocytopenia (ITP) is an autoimmune disease resulting from an 
interaction between a possible genetic predisposition and an environmental trigger 
with subsequent immune dysregulation involving humoral and T- cell immune 
dysfunction. The trigger varies from an unknown cause to a wide range of factors 
such as infections. In the end, a combination of both increased platelet destruction 
and inadequate production is responsible for ITP.21 A number of factors have been 
identified culminating in low platelet counts. These include loss of immune tolerance 
to autoantigens with antibody production and subsequent destruction of platelets by 
the reticuloendothelial system, direct lysis of platelets, suppression of 
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megakaryocytes and reduction in thrombopoietin secretion. This multiplicity of 
mechanisms or pathways explains the heterogeneous pattern of clinical presentation 
and response to therapy observed in ITP patients.22 
 
1.5.1 Antiplatelet auto-antibodies in ITP 
The hallmark of the diagnosis in ITP is the presence of autoantibodies directed 
against platelets. Earlier studies in the 1970s showed increased production of 
antibodies, mainly of the Immunoglobulin G (IgG) class in about 90% of ITP 
patients.23 However, with the newer more sensitive tests, autoantibodies are 
detected in only 60% of patients.24 This finding underscores the success of 
immunosuppressive therapy such as corticosteroids and splenectomy in the 
management of this disorder. Specifically, the autoantibodies are directed against 
platelet glycoprotein (GP)IIb/IIIa, GPIb/IX and others like GPIa/IIa, GPIV, and GPV.21 
It has also been shown that megakaryocytes are a target of these autoantibodies in 
studies by McMillan et al, Rabellino et al and Vinci et al in the 1970s.25,26,27 The 
observation that platelet production is not increased in the face of accelerating 
platelet destruction gives further credence to the fact that megakaryocytes are also 
suppressed.22 
 
1.5.2 T- cell dysfunction in ITP 
The suspicion that T -cell dysfunction may play a role in the pathogenesis of ITP had 
initially been reported by different study groups but it was only in 2003, that the study 
by Olsson et al demonstrated a cytotoxic T lymphocyte mediated thrombocytopenia 
in ITP patients in whom autoantibodies were not detected. They observed in an in 
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vitro study that patients with active disease had peripheral blood T-cells that could 
bind to platelets resulting in their destruction.3,28,29 
 
In addition, T cells are also implicated in antibody production via CD4 Th0/ Th1 
activation, associated with reduced peripheral Th2 and T-regulatory cells and 
impaired susceptibility to apoptosis. The net effect is promotion of antigen 
presentation and perpetuation of the pro-inflammatory milieu with cell-mediated and 
complement-fixing IgG responses. Loss of immune tolerance by T-cells to 
autoantigens is the basis for immune dysregulation in ITP.3,21,22,30,31 
 
1.5.3 Defective Thrombopoiesis in ITP 
Studies by Emmons et al and Kosugi et al in 1996, independently observed that 
thrombopoietin levels are normal or slightly increased in ITP in contrast to the 
expected elevated levels, if the only mechanism was peripheral destruction, implying 
a defective thrombopoiesis in this condition.32,33 
 
Endogenous thrombopoietin (TPO) which is produced primarily in the liver is the 
main regulator of megakaryocytopoiesis and platelet production.34 As TPO is being 
produced, it is constantly used up by megakaryocytes and platelets. Thrombopoietin 
deficiency can either be primary where there is decreased production from liver 
disease or a functional deficiency resulting from rapid clearance by megakaryocytes 
and platelets.35 The lower-than-expected level of TPO observed in ITP is thought to 
be due to a functional TPO deficiency.36-39 
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This discovery paved way to the development of thrombopoietin receptor agonists 
(TPO-RAs) which have proven effective in the management of ITP.40 
 
1.5.4 Variable pathogenesis of thrombocytopenia in secondary ITP 
The potential to initiate an autoimmune response and antibody production in 
secondary ITP results from different mechanisms. A common mechanism relating to 
most infectious causes of secondary ITP such as HIV, HCV and helicobacter pylori is 
as a result of production of cross reactive antibodies. This mechanism is otherwise 
known as molecular mimicry. The inciting organism shares similar antigenic proteins 
with some surface receptors on platelets such as GPIIb/IIIA, resulting in the 
production of antibodies against the inciting agent binding to platelets.41-46 
The mechanism in autoimmune diseases such as SLE, Antiphospholipid syndrome 
and Evans syndrome is de novo autoantibodies cross reacting with platelets.47-50 
Furthermore, certain haematological disorders associated with immunodeficiency 
(e.g. CLL, CVID and ALPS) produce antibodies that cause platelet destruction.51-54 
 
Non immunologic mechanisms also contribute to thrombocytopenia in some cause of 
secondary ITP. This includes cytopathic destruction of megakaryocytes by HIV and 
inadequate thrombopoietin secretion in chronic liver disease from viral hepatitis C 
infection.34,45 In both instances, the result is impaired platelet production. 
 
1.6 Clinical presentation 
The clinical presentation in adults may be acute or insidious in onset. About 80% of 
patients go on to develop chronic ITP. Spontaneous remissions occur in 5 - 11% of 
adults, mostly in the first year after diagnosis.55,58 In general, there is an inverse 
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relationship between remission and the duration of the disease, so that the chances 
of remission decline as the disease progresses.56 
 
Immune Thrombocytopenia (ITP) can be asymptomatic with no clinical features of 
bleeding in 20-40% of patients.9,13,21 This is because bleeding is uncommon when 
platelet counts are above 30 x 109/l.  
The most frequent hemorrhagic manifestation in ITP is purpura. Purpura broadly 
encompasses any kind of mucocutaneous bleed, i.e. skin and/or mucous membrane. 
Thus epistaxis, gum bleeding and sub-conjunctival bleeding are all considered as 
purpura according to IWG. The presence of any bleeding necessitating treatment in 
ITP patients is now regarded as severe ITP. Terminologies such as mild or moderate 
ITP have been discarded.57 
 
The incidence of major bleeding events such as intracranial hemorrhage is low; 
being 1.6% in one long term observational study.58 The platelet count remains the 
best known predictor of bleeding events in ITP. 
 
1.7 Management 
The decision to initiate treatment is primarily based on whether the patient is 
symptomatic (bleeding) and the level of the platelet count (< 30 x 109/l). The goal of 
treatment is to stop the bleeding and increase the platelet count to a safe level and 
not necessarily to achieve a normal platelet count. 
 
Newly diagnosed ITP refers to disease from diagnosis to 3 months. In this phase of 
the disease, corticosteroids (CS) are the mainstay of treatment. Corticosteroids act 
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by suppressing antibody production and reticuloendothelial phagocytic function in the 
spleen and bone marrow. They also improve vascular integrity by acting directly on 
blood vessels93.  Corticosteroids used in ITP include: prednisone, dexamethasone 
and methylprednisolone. Prednisone is the preferred initial treatment, at a dose of 1-
2 mg/kg/day x 10-14 days (up to 21 days). Prednisone is then tapered over the next 
4 to 6 weeks. Alternative treatments include dexamethasone – 40 mg daily orally/IVI 
x 4 days or methylprednisolone – 1g daily IVI x 3 days. Platelet transfusions are 
reserved for patients with severe/very severe thrombocytopenia who are actively 
bleeding or who have recent onset ‘red purpura’ such as oral haemorrhagic bullae.  
 
For emergency treatment, intravenous immunoglobulin (IVIg) and IVI/oral CS should 
be used in combination. Platelet transfusions should be administered (1 unit single 
donor apheresis platelets) in the bleeding patient with severe thrombocytopenia. 
Another option that may be considered where the patient continues to have active 
bleeding despite the above measures (i.e. CS, IVIg, platelet transfusion), is an  
emergency splenectomy. However, this is rarely necessary. 
 
Persistent ITP refers to disease that persists beyond 3 months up to 12 months. 
Treatment should be considered in symptomatic patients and if the platelet count is 
<30 x 109/l. Treatment options include CS or IVIg if used successfully previously. CS 
are preferred over IVIg, as the benefit of IVIg is likely to be temporary (short-lived) 
and at a much higher cost. Second line immunosuppressive agents (such as 
azathioprine and mycophenolate mofetil), should be considered as steroid sparing 
agents. If the above therapy proves unsuccessful, other second line agents such as 
cyclophosphamide, danazol, vincristine etc. may be considered. Rituximab and TPO-
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receptor agonists (TPO-RAs) used as bridging therapy are further options if not 
prohibited by cost considerations. It is preferable to defer splenectomy to beyond 6 
months and ideally to beyond 12 months, as a small proportion of patients may 
achieve spontaneous remission during the persistent phase of disease. The choice 
of second line therapies is based on the experience of the clinician, efficacy and 
safety of the drug, availability, cost and patient preferences.59,60 
 
Chronic ITP refers to disease that persists/continues for more than 12 months. It is 
likely that the patient may have been on intermittent CS, and/or other 
immunosuppressive or second line therapy, with a variable clinical response. The 
three major treatment options for chronic ITP include TPO-RAs, rituximab and 
splenectomy. Each of these options has advantages and disadvantages and 
treatment must be tailored and individualized to the patient with chronic ITP.  
 
1.7.1 Thrombopoietin receptor agonists (TPO –RAs) 
Two TPO-RAs are available for use in ITP, romiplostim and eltrombopag. They bind 
to the thrombopoietin receptor causing proliferation and differentiation of 
megakaryocyte progenitor stem cells similar to the action of endogenous 
thrombopoitin.61,62 Romiplostim is available as a weekly subcutaneous injection at a 
dose of 3-10ug/kg, while eltrombopag is an oral agent taken daily at a dose of 30-
50mg.  
 
These agents are effective in both splenectomised and non-splenectomised patients 
with a response rate of up to 88%.  However, the response is delayed for at least 2 
weeks and an indefinite duration of treatment is required to achieve a durable 
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response.62,63  In one randomized controlled trial, patients treated with romiplostim 
had a higher quality of life with less bleeding and fewer transfusions compared to the 
standard first line medical care94. The most feared complication of TPO-RA is 
progressive bone marrow fibrosis but clinical trials suggest that the incidence is low.  
Other complications include, headache, rebound thrombocytopenia following abrupt 
discontinuation of drug, increased incidence of arterial and venous thrombosis and 
with the use of eltrombopag, there is a risk of hepatotoxicity.64-67 
 
1.7.2 Rituximab 
Rituximab is an anti-CD20  monoclonal antibody used as an ‘off- label’ indication in  
patients with ITP.  Rituximab targets CD-20 positive B-cells, resulting in B-cell 
depletion. From the experience of its use in lymphoma and ITP trials, it is a safe and 
relatively well tolerated drug. Rituximab induces a one year CR in 44% of patients 
with a single course of treatment (375mg/m2 weekly for 4 weeks).68-73 
Its efficacy is not reduced with repeated use in patients who previously responded 
and those who have had a splenectomy, making it a useful option not only in 
persistent and chronic ITP, but also in refractory ITP.31,74 The predictors of response 
as suggested in the literature include young patients, prior response to CS therapy 
and early use of rituximab in the course of ITP.  Also, the combination of rituximab 
with high dose dexamethasone has shown improved response rates of 71% and a 
durable response of 57%.74-76 
 
The most common complication of rituximab is the first infusion reaction seen in 10-
15% of patients. This can be prevented by pre-medication with diphenhydramine and 
paracetamol, as well as a slow infusion rate, over several hours. Rarely, the use of 
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rituximab has been associated with life threatening infections such as fulminant 
hepatitis B infection, pneumocystis jirovecci pneumonia, parvovirus B19 infection 
and progressive multifocal leukoencephalopathy.77 A mortality rate of 2.9% was 
reported in one study mostly related to infections. However, many of these patients 
were on prior immunosuppressive therapy which may have confounded this 
finding.75 In general, rituximab is considered a safe and effective drug for ITP. 
 
1.7.3 Splenectomy 
Splenectomy is the most definitive therapy for ITP. It has the highest likelihood of all 
the current treatment options of producing a cure. It is effective for persistent and 
chronic ITP after failure of CS therapy. It is recommended that splenectomy be 
delayed for at least 6 months (and preferably 12 months) from diagnosis due to the 
chance of a spontaneous remission – 5-11%.55,58 
The overall response rate is 70-90% (CR 50-60%, PR 20-30%, relapse rate 15%).58 
Open splenectomy and laparoscopic splenectomy have similar efficacy. One 
disadvantage of laparoscopic  splenectomy is inability to look for accessory 
splenectomy at surgery, however, it has fewer surgical complications, including less 
postoperative pain, earlier general diet tolerance and shorter hospital stay.77,78 The 
risk of OPSI (overwhelming post-splenectomy infection) is 1.4-fold increased in the 
first year after splenectomy.77 Vaccination against S. pneumoniae, N. meningitides 
and H. influenza are recommended two weeks prior to the procedure.79 If relapse 
occurs post-splenectomy, accessory splenic tissue (splenunculi) should initially be 
sought and excluded.  
14 
 
The advantages and disadvantages of splenectomy are tabulated in Table 1.2 and a 
check list is also included where splenectomy is contemplated/indicated or has been 
performed –(see Table 1.3 on page 16).77 
Table 1.2 Advantages and disadvantages of splenectomy as a therapeutic 
option in ITP 
 ADVANTAGES DISADVANTAGES  
Splenectomy  
- Effective, tried and tested 
therapy 
 
- Most definitive therapy in 
 ITP 
 
- May be curative 
 
- Response rate 70-90%; CR 
 50- 60%; PR 20-30% 
 
- Approximately 60% of 
patients remain in 
 remission 5-10 years 
  after splenectomy – an 
 outcome that is not 
 superseded  by any 
  other therapy 
 
- High response rate 
confirmed in local 
 studies16,80 
 
- Recommended for adults 
Who have failed CS therapy 
 
- No major cost consideration  
 
- No further therapy required 
in  complete responders 
 
- A safe option in responding 
   patients who contemplate 
  pregnancy 
 
- Suitable in young, middle- 
aged  adults 
 
- Removal of relatively ‘healthy’ 
organ 
- Irreversible  
- Response may be 
 unpredictable  
- Relapse rate: up to 15% 
- Surgery - related mobidity and  
   mortality (less with 
 laparoscopic splenectomy) – 
 includes bleeding, 
   infections and thrombosis  
- OPSI (overwhelming post  
   splenectomy infection) in 
 small minority of patients 
- Increased risk of 
 thromboembolic  events 
- Other adverse events include: 
  Pulmonary hypertension  
 
Caution / ?contraindications  
- Significant co-mobidities that 
   increase risk of complications 
 
- Elderly patients have a higher 
 rate of complications, e.g. 
 VTED  
 
- Increased risk of infection in 
Patients with 
 immunodeficiency states e.g. 
   CVID, Hepatitis C, HIV 
   (however, successful 
splenectomy has been 
 performed in carefully 
    selected patients locally and 
    elsewhere)    
 
 
 
 
15 
 
Table1.3 Check list for splenectomy patients  
A. Before splenectomy Intervention 
Education regarding 
procedure and possible 
complications. Discuss 
laparoscopic versus open 
splenectomy 
Consider antibiotic cover for S. peumoniae and H 
influenza if clinically indicated. Use augmentin or a 
cephalosporin or a quinolone 
Vaccination  Vaccination against S. pneumonia, N. meningitides 
and H. influenza type b, ideally 14 days before 
scheduled splenectomy 
Elevation of platelet count Increase platelets to >50x109/l by using CS, IVIg, 
other treatment. This may not always be 
necessary, depending on the surgeon. Procedure 
can be safely performed at lower platelet counts 
with platelet transfusion administered at time of 
clamping the splenic vessels 
Thrombosis risk Consider appropriate thrombo-prophylactic 
measures 
Imaging/platelet 
sequestration studies 
111In-labelled platelet sequestration studies if 
available 81 
B. After splenectomy Intervention 
Antibiotic prophylaxis  Postoperative antibiotic prophylaxis for 2 weeks or 
until the risk of infection is abated. In younger 
individuals, long-term antibiotic prophylaxis may be 
considered up to the age of 21. Antibiotics may 
also be considered in adults for the first two years 
post-splenectomy. 
Patients should be educated about 
infections/OPSI, and encouraged to wear a 
bracelet indicating ‘splenectomy’ 
 Where long term antibiotic prophylaxis is not used, 
patients should be provided with a short 
course/supply of antibiotics which could be used at 
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home at the earliest onset of fever/infection, prior 
to seeking further medical attention   
Thrombo-prophylaxis Good hydration, early mobilization, mechanical 
prophylaxis (IPC).  Consider anticoagulants 
(LMWH) once platelet count  has increased 
(haemostasis secured/no bleeding) if any risk 
factors for thrombosis are present or there is a 
rapid increase of the platelet count into the 
thrombocytosis range   
Discontinuation of other 
treatments  
Gradual tapering of CS, tapering and 
discontinuation of TPO-RA  
Revaccination Annual ‘flu’ vaccine. Booster vaccine for S. 
pneumonia every 5  years 
Relapse after splenectomy Look for accessory spleen – technetium scan  
Regular follow up  Monitor platelet counts post-surgery: every few 
days in the first week to 10 days; then  2 weekly x 
1 month, monthly x 3 months,  3 monthly x 1 year 
and at least 6-12 monthly thereafter. Check platelet 
count at any time in symptomatic or bleeding 
patients  
 
A number of factors have been described in the literature as predictors of outcome 
following splenectomy. Younger patient have the best response to splenectomy with 
the lowest complication rates compared to elderly individuals who usually have 
associated co-morbidities. A high platelet count in the first 10-14 days after 
splenectomy also confers a favourable response. Prior poor response to multiple 
agents, longer duration of disease and secondary ITP are associated with poorer 
outcomes.58,82-89 
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The type of splenectomy procedure impacts on the morbidity and mortality following 
splenectomy. A series by Kojouri et al, reported a complication rate of 12.9% with 
laparotomy (open splenectomy) and 9.6% with laparoscopic splenectomy. However, 
mortality was significantly low (1% for laparotomy versus 0.2% for laparoscopic 
splenectomy).58 The complications include intra-operative complications such as 
bleeding and injury to internal organs, infections (including OPSI) and post 
splenectomy thrombotic events.  
 
Infections caused by encapsulated organisms are always a concern following 
splenectomy. In a retrospective study of 9976 ITP patients (splenectomised and non-
splenectomised), the cumulative incidence of sepsis in patients who had a 
splenectomy was 11.1% versus 10.1% in non-splenectomised patient.90 This study, 
together with the study by Vianelli et al, reported a very low mortality rate from 
infection, with the latter study showing zero mortality from infection.82,90 
 
A potential concern in our setting is the perceived increased risk of infections 
following splenectomy in HIV sero-positive patients. Studies that looked at response 
and complications following splenectomy showed no significant difference between 
HIV positive and HIV negative patients.16,79,92 
 
Patients who have refractory ITP, having undergone splenectomy carry a poorer 
prognosis, although some of these patients may eventually achieve remission in the 
long term. Mortality is related to both complications of splenectomy and toxicity of 
therapy.90,91 
 
18 
 
1.8 Aims and objectives of the study 
 
1.8.1 Aims 
To study the impact of splenectomy as a therapeutic modality in patients with ITP 
 
1.8.2 Objectives 
a. To assess the impact (specifically the indication, timing, outcome - response and 
duration of response, complications etc.) of splenectomy in ITP 
b. To compare the efficacy and safety of laparoscopic versus open splenectomy in 
ITP 
c. To compare the efficacy, safety and outcome of splenectomy in primary and 
secondary ITP 
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CHAPTER 2: PATIENTS AND METHODS 
 
2.1 Study Design 
This is a retrospective study of all splenectomised patients with ITP who were 
diagnosed and managed at the Clinical Haematology unit, Department of Medicine, 
Chris Hani Baragwanath Academic Hospital, between 01/01/1986  and 31/12/2014 
(29 years). 
 
2.2 Study Population 
The study included all patients that had a splenectomy for ITP and where sufficient 
data was available for review of the patients. There were 64 patients, of whom 56 
were evaluable. 
 
2.3 Inclusion Criteria 
Patients > 18 years of age who were diagnosed with ITP and who have had a 
splenectomy  
 
2.4 Exclusion Criteria 
a. Patients < 18 years of age 
b. Patients who have missing and/or incomplete records/data 
 
2.5 Description of Methodology      
A retrospective review of records of patients who had a splenectomy for ITP, during 
the aforementioned study period was performed. Permission was obtained from the 
Clinical Haematology Unit, the Department of Medicine and the CHBAH authorities. 
20 
 
A standardised questionnaire (see Appendix B) was used to document the following 
characteristics, on each of the patients: 
a. Demographics 
b. Diagnosis–primary or secondary ITP and cause of secondary ITP 
c. Indication for splenectomy 
d. Timing of splenectomy (i.e. time from diagnosis to splenectomy) 
e. Type of splenectomy–open or laparoscopic  
f. Details of treatment and number of lines of treatment pre-splenectomy 
g. Clinical and laboratory parameters prior to and post-splenectomy 
h. Specific preparation of patients prior to splenectomy (re: target platelet 
counts, vaccination, platelet transfusion during procedure) 
i. Peak post-splenectomy platelet count and response in the immediate post-
splenectomy period (10-14 days) 
j. Antibiotics peri and post-splenectomy 
k. Therapies used peri and post-splenectomy (e.g. corticosteroids, IVIg) 
l. Thrombo-prophylaxis 
m. Complications – immediate and delayed (intra-operative, post-operative – 
sepsis, bleeding, thrombosis, and relapse) 
n. Outcome (based on response criteria) 
o. Mortality related to splenectomy or other reasons for mortality 
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The response criteria in ITP are as defined in Table 2.1 below. 
Table 2.1 Response criteria in ITP 
a. Complete response (CR) Platelet count ≥ 100 x 109/l and absence of bleeding 
b. Partial response (PR) Platelet count ≥ 30 x 109/l and at least 2 - fold 
increase of the baseline count and absence of 
bleeding 
c. No response (NR) Platelet count < 30 x 109/l, or less than 2-fold 
increase of the baseline count or bleeding 
d. Loss of CR or R Platelet count below 100 x 109/l or bleeding (from 
CR) or below 30 x 109/l or less than 2-fold increase 
of the baseline count or bleeding (from response) 
e. Time to response Time from starting treatment to time of achievement 
of CR or R 
f. Duration of response Measured from the achievement of CR or R, to loss 
of CR or R 
g. Refractory ITP Failure to achieve R or loss of response after 
splenectomy; ongoing need of treatment to minimize 
the risk of clinically significant bleeding 
 
The patient’s name and personal details were kept confidential. The file numbers 
were given a numerical coding system in order to maintain confidentiality. 
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2.6 Data Analysis 
Data was captured on an Excel spreadsheet and exported into SPSS version16.0 
(originally, Statistical Package for the Social Sciences and renamed Statistical 
Product and Service Solutions) software. 
 
Descriptive statistics such as the frequency distribution, median and standard 
deviation were used to transform the raw data into a form that is easy to understand 
and interpret.  Frequency distributions were presented graphically as either pie or 
bar charts for categories such as patient gender with only male and female 
categories. In cases where there were more categories such as site of bleeding, bar 
graphs were used to present the results graphically.  
 
A paired sample t-test was conducted to assess whether there was a significant 
difference between the highest platelet counts 14 days post splenectomy and the 
platelet counts prior to splenectomy as well as the difference between the platelet 
counts one year post splenectomy and the platelet counts prior to splenectomy. The 
paired t-test examines if the mean of the differences is different from zero (no 
difference). If the p-value of the t-test is less than 0.05 (the significance level), then 
the difference between the two samples is considered to be significant. If the p-value 
is greater than 0.05 then the null hypothesis cannot be rejected and it is concluded 
that there is no difference between the two means. 
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2.7 Ethics Approval 
Ethics approval was granted by the Human Research Ethics Committee (HREC) of 
the University of the Witwatersrand (Clearance Certificate no. M150590). Informed 
consent was not needed from the patients due to the retrospective nature of the 
study. 
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CHAPTER 3: RESULTS 
 
3.1 Demographics 
Of the 56 splenectomised ITP patients, 77% were females (n=43) and 23% were 
males (n=13). 
The median age of the patients was 29 years with a median age of 29 with a range 
of 18-53 years.  
The ethnic breakdown of the patients was as follows: The vast majority of the 
patients were Blacks (n=49, 87.5%), while (n=4, 7%) were Whites, a smaller number 
(n=2, 3.6%) were of Indian origin and (n=1,1.8%) patient was of Mixed race 
(coloured). The demographic profile table is shown below. 
Table 3.1: Demographic profile 
Demographics     Frequency     Percent 
Gender 
             Male 
 
      13 
 
      23% 
             Female       43       77% 
Ethnicity  
             Black 
 
      49 
 
     87.5% 
             White        4        7% 
             Indian        2       3.6% 
             Mixed race        1       1.8% 
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3.2 Clinical Presentation 
Bleeding manifestations constituted the most common clinical presentation (n=45, 
80%) on admission. This decreased to (n=35, 62.5%) prior to splenectomy and 
further to (n=4, 7.7%) 1 year post-splenectomy. The site of bleeding was mainly 
cutaneous (32 of 45, 71%) at presentation, and (27 of 35, 77%) prior to splenectomy.  
None of the splenectomised cohort had lymphadenopathy, hepatomegaly or 
splenomegaly. 
 
Table 3.2: Clinical features according to timelines 
  First 
Presentation 
Prior to 
Splenectomy 
1-year Post-
Splenectomy 
Bleeding n= 56 56 52 
 45 (80.4%) 35 (62.5%) 4 (7.7%) 
asymptomatic 11 (19.6%) 21 (37.5%) 46 (88.5%) 
Site of 
Bleeding 
 45 35 4 
skin 32 (71%) 27 (77%) 4(100%) 
sub-
conjunctival 
1 (3.1%) 0 (0.0) 
 
epistaxis 7 (15.6%) 5 (14.3%) 
 
gum 1 (3.1%) 0 (0.0%) 
 
menorrhagia 3 (6.7%) 1 (2.9%) 
 
haematuria 1 (3.1%) 0 (0.0%) 
 
ICB 0 (0.0%) 2 (5.7%) 
 
Fever n= 56 56 52 
 2 (3.6%) 1 (1.8%) 0 (0.0%) 
Anaemia n= 56 56 52 
 12 (21.4%) 7 (12.5%) 0 (0.0%) 
ICB- Intra-cerebral bleed 
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Of the 56 patient, three patients (5.4%) were HIV sero-positive, while one patient 
(1.8%) had mixed mitral valve disease. Eleven patients (19.6%) had an underlying 
autoimmune disease. Of these 11 patients, nine were diagnosed with systemic lupus 
erythematosus (SLE), 1 patient had an auto-immune Haemolytic anaemia (Evan’s 
syndrome) and another patient had mixed connective tissue disease (MCTD). None 
of them had a lymphoproliferative disorder or Tuberculosis (TB). 
Table 3.3: Co-morbid diseases 
  
Frequency  Percent 
TB                   0        0.0 
HIV 
      positive        3        5.4 
      negative       53       94.6 
Auto immune 
Disease 
                 11       19.6 
Type of Auto 
immune Disease 
SLE        9       81.8 
AIHA        1        9.1 
MCTD        1        9.1 
LPD                    0        0.0 
Mixed Mitral Valve 
disease 
                  1        1.8 
HIV- Human Immunodeficiency Virus; LPD- Lymphoproliferative disorder; SLE- Systemic Lupus 
Erythematosus, AIHA- Autoimmune Haemolytic Anaemia; MCTD- Mixed Connective Tissue Disease 
 
Prior to splenectomy, all the 56 patients (100%) were on prednisone, 11 patients 
(19.6%) had received IV immunoglobulin, 35 patients (62.5%) were treated with 
azathioprine and only 5 patients (9%), received rituximab. 
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A year post splenectomy,  the number of patients receiving prednisone decreased to 
14 patients (26%),  8 patients (14.8%) were still on azathioprine, with only 2 patient 
on rituximab as a result of poor response to splenectomy (partial or no response). 
Table 3.4: Drug history prior to splenectomy and 1 year after splenectomy 
 
Drugs Prior to 
Splenectomy 
Drugs 1-yr Post- 
Splenectomy 
Prednisone 
56 54 
56 (100%) 14 (26%) 
Solumedrol 
  
20 (35.7%)         - 
Danazol 56 54 
 
11(19.6%) - 
Azathioprine 
56 54 
35 (62.5%) 8 (14.8%) 
Rituximab 
56 54 
5 (9%) 2 (3.7%) 
 
 
3.3 Types of ITP 
Most of the patients who had a splenectomy were diagnosed with primary ITP (n=42, 
75%), while secondary ITP was encountered in the remainder (n=14, 25%).  
Of the 14 patients that had secondary ITP, 11 patients (79%) had an underlying 
autoimmune disease, while 3 patients (21%) were sero-positive for HIV. 
Table 3.5: Secondary ITP 
  
Frequency % 
Cause of 
secondary ITP 
Auto-immune 11 79 
HIV 3 21 
 
In ‘classical’ primary ITP, a bone marrow aspirate and trephine (BMAT) is not always  
performed. However, in this study, forty-seven patients (84%), had a (BMAT). 
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3.4 Time to splenectomy 
It took on average, 27.9 months from the diagnosis of ITP to splenectomy (range: 1 
month - 156 months). Half of the patients took 12 months or longer to splenectomy 
(median = 12 months). Fourteen patients, constituting 25% of the total, had their 
splenectomy after 24 months. 
Table 3.6: Time to splenectomy according to intervals in months 
Interval (months) Frequency % 
0 - 3 months 8 14.3 
3 - 6 months 4 7 
6 - 9 months 10 17.9 
9 - 12 months 10 17.9 
18- 24 months 10 17.9 
> 24 months 14 25 
Total 56 100.0 
 
 
3.5 Types of splenectomy 
Open splenectomy was performed in the vast majority of patients (91%). Three 
patients had a laparoscopic procedure, while 2 patients had their laparoscopic 
surgery later converted to open splenectomy due to complications.  
Table 3.7: Types of splenectomy 
Types of splenectomy Frequency % 
Laparascopic 3 5.4 
Laparascopic/ Open 2 3.6 
Open 51 91 
Total 56 100.0 
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3.6 Number of classes of treatment used prior to splenectomy 
In this study, most patients received up to three different classes with a minority 
receiving a fourth or fifth drug class prior to splenectomy (see Table 3.10 on page 
34). 
Table 3.8: Number of classes of treatment used prior to splenectomy 
Variable Classes Number % 
Classes of treatment prior to 
splenectomy 
1 22 39.3% 
2 18 32.1% 
3 10 17.9% 
4 4 7.1% 
5 2 3.6% 
 
3.7 Indication for splenectomy 
The indication for splenectomy was mainly due to poor response to medical therapy 
(partial and no response, relapse, steroid dependency with side effects in order to 
maintain platelet count above 30 x 109/l) in 55 patients (98.2%). In 1 patient, the 
indication was due to poor compliance to therapy. The breakdown of indication for 
splenectomy as relates to CS therapy is shown in figure 3.6 below. 
30 
 
 
 
Figure 3.6: Indication for splenectomy as relates to CS therapy 
 
3.8 Preparation for splenectomy 
Most of the patients (87.5%) had a platelet transfusion peri-splenectomy (i.e. shortly 
before or during the procedure) as shown in the table below.  
Table 3.9 Peri-operative measures 
Antibiotics peri-splenectomy and up 
to 2 weeks post splenectomy 56 100% 
Pneumococcal vaccination 56 100% 
Platelet transfusion 49 87.5% 
Thrombo-prophylaxis 0 0 
 
 
 
Table 3.10: Number of splenunculi detected intra-operatively  
 Frequency % 
Splenunculi 3 5.4 
 
 
60.7%
28.6%
8.9%
1.8%
Steroid dependent
Steroid resistant
Loss of response
Non compliance
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The table below show various complications recorded from splenectomy including 
the mortality. 
Table 3.11: Complications  
 Perioperative Non-operative 
      n       %       n       % 
Infection       2      3.6       9      16.1 
Bleeding       1      1.8       4       7.1 
Thrombosis       0       0       2       3.6 
Death       1      1.8       1       1.8 
 
 
3.9 Response to splenectomy 
The mean platelet counts response according to timelines is summarized below. 
Table 3.12: Platelet count response according to timelines 
 
A paired sample t-test was conducted to compare the platelet count 14 days post 
splenectomy and the platelet count prior to splenectomy. The results are shown on 
page 32. 
 
Mean platelet counts-at presentation                     12 x 109/l 
Mean platelet counts-pre-splenectomy 26 x 109/l 
Mean platelet counts-14 days post- splenectomy 347 x 109/l 
Mean platelet counts-1-year post-splenectomy 231 x 109/l 
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Table 3.16: Paired sample t-test for highest platelet count 14 days post- 
splenectomy against the platelet counts prior to splenectomy 
Paired Sample Statistics Paired Sample  
t-Test 
 Mean Number Standard 
deviation 
t-
value 
p-value  
(2 Sided) 
Highest platelet count 
14 days post 
splenectomy 
347.2 56 177.7 
10.8 0.000 
Platelet count  prior 
to splenectomy 
26.2 56 31.6 
 
It was noted that the highest platelet count 14 days post splenectomy were on 
average 347.2 ± 177.7, compared to 26.2 ± 31.6 prior to splenectomy. The 
difference between the two is significant with a p-value = 0.00 
 
A paired sample t-test was also conducted to compare the platelet count one year 
post splenectomy and the platelet count prior to splenectomy. The results are shown 
in table 3.14. 
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Table 3.14: Paired sample t-test for platelet count one year post splenectomy 
against the platelet count prior to splenectomy 
Paired Sample Statistics Paired Sample  
t-Test 
 Mean Number Standard 
Deviation 
t- 
value 
p-value  
(2 Sided) 
Platelets counts one 
year post splenectomy 
231.2 56 162.6 
7.4 0.00 
Platelet counts prior to 
splenectomy 
26.2 56 31.6 
 
 
The result shows that the platelet counts one year post splenectomy (mean = 231.2 
± 162.6) were significantly higher than the platelet counts prior to splenectomy 
(mean = 26.2 ± 31.6). The difference between the two is significant with a p-value of 
0.00 
The status of disease at the last visit is depicted in Figure 3.2 on page 34. Thirty 
seven patients, 66% were in complete remission, 7 patients (12.5%) had a partial 
remission while there was no response and loss of response in 3 patients each. Two 
patients died (3.6%) and in 4 patients (7.1%), the response was unknown. 
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Figure 3.2 Status of disease at last visit  
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CHAPTER 4: DISCUSSION 
4.1 Introduction 
Splenectomy was the first, definitive, recognized therapeutic modality in ITP, several 
years before the discovery of corticosteroids in the 1950s.9 The role of splenectomy 
as a treatment option has evolved over the last century and it is currently regarded 
as a second line treatment option. 
 
To this effect, the current retrospective study was performed, to assess the impact of 
splenectomy on the management of ITP, in patients at Chris Hani Baragwanath 
Academic Hospital from 1986 to 2014. Of the 343 patients who were diagnosed with 
ITP within the study time frame, 64 patients had a splenectomy (64/343=18.6%).       
 
4.2 Epidemiology 
Similar to many autoimmune diseases where females are predominantly affected, in 
this study, the female to male ratio was 3.3:1. This is the same gender ratio reported 
in the Cape Town splenectomised cohort (Female=56, Male=17)79. The female 
preponderance is also in keeping with the gender distribution of ITP in our institution 
as observed in a recent study by Variava, in which 80% were females, with a female 
to male ratio of 4.2:1.16 The gender differences of ITP were less marked in two 
international studies where the female to male ratio were 1.7:1 and 1.2:195,96. This 
disparity may be ascribed to the increasing number of secondary ITP due to HIV 
infection which is mostly prevalent among women between the ages of 15 and 49 in 
South Africa.97 
 
36 
 
The mean age of these patients was 31 years, in keeping with local South African 
studies.15,16 However, ITP is now being increasingly seen in older patients in the 
Western world with estimated average age of 60 years. The gender difference of a 
female predominance in young and middle aged individuals is also less marked in 
the elderly.13,14 
 
4.3 Clinical Presentation 
The majority of our patients presented with bleeding. Eleven patients (19.6%) were 
asymptomatic at first presentation, having been diagnosed after incidental review of 
their blood counts. Similar to the reports in the literature, the commonest bleeding 
manifestations were mucocutaneous bleeds57. Eighty percent of our patients had 
skin bleeds (n=45), followed by epistaxis (n=7, 15.6%) and menorrhagia (n=3, 6.7%). 
Two patients (3.6%) had an intra-cranial bleed of all the clinical presentations in this 
series of splenectomised patients and 2% of all cases of ITP at our institution as 
reported by Variava16. Both figures are higher than in the US series where the 
incidence of intra-cranial bleed was less than 1%98.   
All the patients satisfied the requirement of initiating treatment for ITP, based either 
on the severity of bleeding or a significant thrombocytopenia (levels < 30x109/l). 
The mean platelet count prior to splenectomy was 26 x109/l, as opposed to 12 x 109/l 
at presentation. The higher mean platelet count prior to splenectomy is a reflection of 
patients being on treatment and the indication for splenectomy not only being a low 
platelet count, but other factors such as steroid dependence with intolerable or 
unacceptable side-effects. 
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None of the patients had lymphadenopathy, splenomegaly or hepatomegaly. Thus, 
the diagnosis of ITP could be made with a high degree of probability on clinical 
grounds alone. Nonetheless, 84% of the patients (n=47) subsequently underwent a 
bone marrow examination to further strengthen the diagnosis and exclude other 
causes of ITP.  
 
Of the 14 patients (25%) with secondary ITP who had a splenectomy, 11 patients 
had an underlying autoimmune disease (9 patients had SLE while concomitant 
autoimmune haemolytic anaemia and mixed connective tissue disease was present 
in 1 patient each, respectively). In this study, the number of HIV sero-positive 
patients who had a splenectomy was low (n=3, 5.4% of all splenectomised patients 
with ITP) compared to what would have been expected with the change in the 
pattern of the aetiopathogenesis of ITP in South Africa. Human immunodeficiency 
virus infection has increasingly become a major cause of secondary ITP. In our 
experience at CHBAH as observed in the study by Variava, secondary ITP 
accounted for 50% of all cases of ITP, of which 40% of cases were due to HIV 
infection. The lower than the expected number of HIV associated ITP requiring 
splenectomy may be attributed to a favourable response to HAART and medical 
therapy or possibly to the concern of increased morbidity, particularly in relation to 
infection, in the setting of splenectomy in HIV seropositive patients. 
 
4.4 Splenectomy and ITP 
Having failed CS, either alone or in combination with other agents, such as second 
line immunosuppressive therapy or IVIg, patients with persistent and chronic ITP 
typically require one of three second line therapies, viz: splenectomy, rituximab and 
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TPO-RAs (e.g. eltrombopag, romiplostim). Of these three modalities, splenectomy 
has the highest efficacy in relation to achieving a cure (based on a sustained, 
complete remission). Up to 90% of patients will show a response to splenectomy, 
and up to two thirds of patients will achieve a complete and durable remission.58 
 
Our study showed a similar outcome with 66% (n=37) achieving a complete 
remission and a further 12.5% (n=7) showing a partial response. There was no 
response or loss of response (relapse) in 10.7% (n=6) of the patients.  
 
The mean platelet count of 231.9 X 109/l, one year post splenectomy was statistically 
significantly higher than the mean platelet count prior to splenectomy (26 X 109/l), 
with a p-value = 0.00.  
 
In those who have a complete and sustained response to splenectomy, splenectomy 
is regarded as being curative, with no need for further therapy. By extension, it is 
therefore cost effective, compared to the newer agents, especially the TPO-RAs, 
which need to be given for a prolonged period of time, prior to possible 
discontinuation.  
 
In the Western world, there is a progressive decline in the rate of splenectomy, 
where cost may not be a limiting factor and where patient preferences play a 
significant role.77 In addition, although splenectomy is a relatively safe procedure, it is 
not without complications. Given the paradigm shift, with ITP occurring in older 
patients in the Western world, there is also a concern about the increased risk of 
thrombotic manifestations post-splenectomy.58 
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Failed CS therapy was the commonest indication for splenectomy in this study in 
keeping with the literature where remission is only expected in 10 to 30% of cases99. 
All of the patients were on CS therapy prior to splenectomy with 22 patients on CS 
therapy alone (39.3%), while the remaining patients had additional therapies. Up to 5 
classes of treatment were used prior to splenectomy. Steroid dependence and 
steroid resistance were noted in 34 and 16 patients, respectively, while 5 patients 
had a relapse or loss of response to CS. The majority of these patients also 
experienced disabling side effects from high doses and prolonged use of CS.  
 
Six patients (10.7%) did not respond to oral and/or IV CS and IV immunoglobulin, 
necessitating splenectomy within a period of three months. Three of these 6 patients 
(5.4% of all splenectomised patients) underwent emergency splenectomy. The 
indication for emergency splenectomy was an intracranial bleed in 2 patients, while 
the third patient had severe, ongoing, active bleeding which did not respond to 
supportive and specific measures, including CS, IV immunoglobulin and platelet 
transfusions. All of these patients had a favourable outcome, following emergency 
splenectomy. 
 
Only one patient underwent splenectomy due to poor compliance to treatment. 
Incidentally, this patient was also diagnosed with mixed mitral valve disease that 
required surgery and anticoagulation. 
 
The average time to splenectomy in this study was 27.9 months. This is significantly 
longer than the previous recommended period of > 6 months from diagnosis. In the 
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newer guidelines, there is a trend to delay splenectomy to more than one year, as a 
small proportion of patients (5-11%) may achieve a spontaneous remission up to 1 
year from diagnosis. This observation is important as it is well documented that time 
to splenectomy is an important predictor of response. The further splenectomy is 
delayed from the diagnosis of ITP, the poorer the response.55,58 
 
The delay to splenectomy in this study may be attributed to the perceived danger 
and complications of surgery, and the removal of an ‘organ’ of the body, which is 
irreversible. 
 
Age at splenectomy is considered to be an independent and consistent predictor of 
response to splenectomy.83 The mean age of the patients prior to splenectomy was 
31 years. Eight patients were older than 40 years of age, and none were older than 
60 years. Only one patient in the age group > 40 years had a poor response to 
splenectomy, as opposed to the observation in the systematic review by Kojouri et 
al, where poor outcomes were reported in patients older than 40 years, in many of 
the case series that were reviewed.58 However, there was lack of standardization of 
variables such as age-group and response to therapy in this reported series.58 More 
so, the age distribution of newly diagnosed chronic ITP in South Africa is clearly 
opposite to that seen in the Western world, where the mean age of presentation is 
57 years.11-14 The younger age at presentation of ITP in our patients (mean of 31 
years) is consistent with a more favourable response to splenectomy. 
 
Another suggested predictor of response is the post splenectomy platelet count, 
within the first 4 weeks after surgery. Five out of the six patients who did not respond 
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to splenectomy had a platelet count < 60 X 109/l, four weeks post- surgery, in 
contrast to the responders in whom the lowest platelet count was 150 X 109/l and the 
highest count was 606 X 109/l.58,82 
Contrary to preference of laparoscopic splenectomy over open laparotomy in most 
centres including the Cape Town study by Antel et al where 62% of their patients 
had laparoscopic  surgery,58,79 In this study the surgical procedure of choice was 
open splenectomy. Ninety-one percent of patients (n=51), had an open splenectomy. 
Only three patients had a laparoscopic splenectomy. Two other patients who initially 
had laparoscopic surgery were converted to open surgery due to suspected intra-
abdominal sepsis. However, this study is unable to comment on laparoscopic 
surgery in view of the small numbers that were exposed to this procedure. 
Nevertheless, the literature suggests that where the expertise is available, 
laparoscopic splenectomy is a better option with less complications and early 
hospital discharge.77,78   
 
The complications recorded in this study were classified as perioperative or non-
operative complications. Three patients (5.4%) had perioperative complications, 
defined as complications related to surgery up to the time of discharge. Of these 
patients, one patient had operative bleeding while the other 2 patients had intra-
abdominal sepsis due to bowel perforation. The non-operative complication rate was 
27% in 15 patients. Nine of these patients (16.1%) had infections, of which 3 
required hospitalization. Two patients (3.6%) had thrombotic manifestations, while 4 
patients had mucocutaneous bleeds. The overall complication rate in our study was 
32.2%. This is much higher than what the literature suggested. The combined 
complication rate for open and laparoscopic splenectomy reported by Kajouri et al 
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was 22.5% (open splenectomy=12.9%, Laparoscopic=9.6%), while Antel et al 
reported a complication rate of 16%.58,79 These differences may be attributed to lack 
of standard definition of what was regarded as a complication across these series 
especially in relation to infections (mild versus severe sepsis) in the follow up period. 
Secondly, the high rate of infections recorded in our study could have been 
confounded by the ongoing need for CS therapy and immunosuppressive agents in 
some patients. 
 
There was no difference in the efficacy, safety and outcome of splenectomy between 
primary and secondary ITP in this study. The majority of the splenectomised patients 
had primary ITP (75%), while the remaining 25% were diagnosed with secondary 
ITP. This is in contrast to the increasing number of secondary ITP patients at our 
hospital, as observed in the study by Variava, where a secondary cause of ITP was 
reported in 50% of the patients, mostly due to HIV infection (40% of all secondary 
ITP).16 The 3 HIV sero-positive patients who had a splenectomy, had a favourable 
outcome. Their CD4 counts were 118/ul, 240/ul and 328/ul, respectively. Although 
this number is very small, our findings are consistent with other studies that looked at 
splenectomy in HIV sero-positive patients versus HIV sero-negative patients, where 
there was no significant difference in mortality post splenectomy.79,92 In the study at 
Groote Schuur Hospital in Cape Town by Antel et al, splenectomy was shown to be 
effective, irrespective of the HIV status. The complications, morbidity and mortality in 
association with splenectomy in this study, were not statistically significantly different 
in the 12 HIV sero-positive patients, compared to the 44 HIV sero-negative 
patients.79 
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Two patients died in this study (3.6% mortality rate). This is higher than the 1% 
mortality rate quoted in the literature.58 As indicated earlier, the first patient was one 
of the two patients that developed sepsis from gut perforation following laparoscopic 
splenectomy. The indication for splenectomy in her was lack of response to 
corticosteroids, including IV Solumedrol and also IV immunoglobulin. She had a 
good platelet count rise post splenectomy (platelet count of 238 on day 11 post-
splenectomy, from a platelet count of 10, prior to splenectomy), with no evidence of 
bleeding. Extended spectrum beta-lactamase producing Escherichia coli (ESBL - 
E.coli) was cultured in her blood, and she unfortunately succumbed to septicaemia 
on day 11, post-surgery.   
 
The second mortality from this study was a woman with refractory ITP requiring 
additional CS therapy and azathioprine. She had a splenectomy 4 years earlier with 
variable platelet counts post-splenectomy and no bleeding manifestations. She 
developed nosocomial pneumonia after being discharged from the hospital 2 weeks 
before, with salmonella sepsis. She also had a significant co-morbidity, having been 
diagnosed with chronic thromboembolic pulmonary hypertension. The cause of her 
death was sepsis. Both patients had primary ITP and were HIV sero-negative. 
 
4.5 CONCLUSION 
The role of splenectomy in ITP continues to be reassuring, particularly in our public 
sector setting, where the newer agents, such as the thrombomimetics, are not yet 
available due to their high cost, and rituximab is used as an off-label indication, after 
failure of CS and immunosuppressive therapy.  Splenectomy is the preferred second 
line therapy after the patient has failed CS therapy.  Although the minority of the 
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patients had a laparoscopic splenectomy, with time and experience, laparoscopic 
splenectomy should become the procedure of choice, especially in conditions such 
as ITP, where the spleen is not enlarged, making the procedure highly technically 
feasible. Furthermore, the outcome for primary versus secondary ITP was equally 
favourable. However, it must be noted that there were significantly lesser numbers of 
secondary ITP patients in this study. 
We believe that the findings are a fair representation of the role of splenectomy in 
ITP, in South Africa, based on a retrospective review from a large single centre, over 
a period of 27 years. This is further corroborated by the findings of the recent 
publication from Cape Town, by Antel et al. 
Therefore, splenectomy remains a feasible and appropriate second-line therapeutic 
modality in ITP. In our setting, it is arguably the second-line treatment of choice, and 
must be considered for patients with persistent and chronic ITP, who have failed 
prior CS therapy. 
 
4.6 LIMITATIONS 
The findings in this study are limited by its retrospective nature. For some patients 
data was missing and files could not be reviewed. Ideally, a larger sample size would 
have added to the strength of this study. In addition, this is a single centre study 
carried out at Chris Hani Baragwanath Academic Hospital, South Africa, therefore 
the findings may not necessarily be applicable to other populations. 
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          APPENDIX B 
DATA COLLECTION SHEET  
A. DEMOGRAPHICS  
Study Number:      
Gender:  Male  Female  
Date of Birth:  D D  M M  Y E A R 
 
Date of Diagnosis: D D  M M  Y E A R 
 
Ethnic Group:  Black  White  Coloured  Asian  Other:  
B. HISTORY  
AT PRESENTATION PRIOR TO SPLENECTOMY 1 YEAR POST-SPLENECTOMY 
OR AT LAST VISIT (IF < 1 YEAR 
POST-SPLENECTOMY)  
Bleeding              Yes  No  Yes  No  Yes  No  
Sites of Bleeding Yes  No  
     
     
Yes  No  
     
     
Yes  No  
     
     
Symptoms of anaemia Yes  No  
      
      
Yes  No  
     
     
Yes  No  
     
     
History of fever/infections Yes  No  
      
      
Yes  No  
     
     
Yes  No  
     
     
 
Past or known history of:  
1. TB Yes  No  
2. HIV Yes  No  
3. SLE Yes  No  
4. LPD Yes  No  
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5. Other comorbid diseases  
        
 
AT PRESENTATION PRIOR TO 
SPLENECTOMY 
1 YEAR POST-SPLENECTOMY 
OR AT LAST VISIT (IF < 1 YEAR 
POST-SPLENECTOMY)  
Is patient on any medication Yes  No  Yes  No  
 
Yes  No  
 
List of medications  
      
      
      
    
    
    
    
     
     
     
     
 
C. EXAMINATION  
AT PRESENTATION PRIOR TO SPLENECTOMY 1 YEAR POST-SPLENECTOMY 
OR AT LAST VISIT ((IF < 1 YEAR 
POST-SPLENECTOMY)   
Pallor Yes  No  Yes  No  Yes  No  
Jaundice Yes  No  Yes  No  Yes  No  
Lymphadenopathy Yes  No  
     
     
Yes  No  
     
     
Yes  No  
     
     
Hepatomegaly Yes  No  
      
      
Yes  No  
     
     
Yes  No  
     
     
Splenomegaly Yes  No  
      
      
Yes  No  
     
     
Yes  No  
     
     
Active bleeding Yes  No  
      
      
Yes  No  
     
     
Yes  No  
     
     
Petechiae  Yes  No  
      
      
Yes  No  
     
     
Yes  No  
     
     
Purpura  Yes  No  
      
      
Yes  No  
     
     
Yes  No  
     
     
Ecchymoses Yes  No  
      
      
Yes  No  
     
     
Yes  No  
     
     
Haematomas Yes  No  
      
      
Yes  No  
     
     
Yes  No  
     
     
60 
 
Other bleeding Yes  No  
      
      
Yes  No  
     
     
Yes  No  
     
     
 
Any other relevant clinical features related to:  
I. Secondary ITP  
II. Complications of ITP 
III. Comorbid disease  
            
            
            
  
C. DIAGNOSIS  
1O ITP  Yes  No  
2O ITP   Yes  No  
If 2o ITP  – cause of 2o ITP          
  
Was BMAT done ? Yes  No  
Was any abnormality detected? Yes  No  
Details of abnormality           
 
D. SPLENECTOMY  
Date of diagnosis of ITP:           
Date of splenectomy:            
Number of lines of prior treatment used:         
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Prior treatments used:           
Name Dose Route Duration Response  
     
     
     
     
 
Indication for splenectomy:           
Type of splenectomy: Open:    Laparoscopic:      
Antibiotics used peri/post-splenectomy: Yes  No  
   If yes: Duration of use: 2 weeks only       2 years      Lifelong         Other  
 
Vaccination peri/post- splenectomy:   Yes  No  
   If yes: Type of Vaccination/ Time prior to or after splenectomy 
   Pneumococcal    
   Meningococcal      
 
Therapies used immediately prior to splenectomy 
          Corticosteroids Yes  No  
          (type/dose/duration/route)         
IVIg Yes  No          
          Other Yes  No          
           Platelet transfusions used: Yes  No       
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Platelet counts: 1 week prior to splenectomy       
      Day of splenectomy          
      Highest count in the first two weeks post-splenectomy (count; day)   day:  
Was thromboprophylaxis used? Yes  No  
      If yes, type of thrombo-prophylaxis: 
            Mechanical only             Aspirin             Heparin (LMWH)             Other  
            
When was thrombo-prophylaxis used?  
Peri-splenectomy Peri and post-splenectomy Post-splenectomy 
             Duration of thrombo-prophylaxis    
Were splenunculi/accessory spleens detected at surgery Yes  No  
       Number and location of splenunculi/accessory spleens, if detected ? 
At surgery: Bleeding      
                     Infection     
Post surgery: Wound sepsis           
                         Infection      
OPSI/other infections         
Thrombosis post-splenectomy          
Other complications post-splenectomy         
Platelet count at 1 year post-splenectomy         
Platelet count at last visit (duration from date of splenectomy):      
Response to splenectomy: CR          
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                                           PR        
                        NR          
                                           Duration of response:        
Outcome  
Date:      
Alive  Deceased  Lost to follow up   
If deceased:  
Cause/s of death:            
             
             
Survival time (date of diagnosis – date of death and date of splenectomy to date of 
death) in 
months:       ;        
If lost to follow up:  
Date last seen:      
Status of disease at last visit (e.g. remission, relapse):       
 
 
 
